

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for
Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – May 12, 2018
Data through : May 12, 2018
Table 4 – Progression to Step 2 by Site**

	Overall	Baylor	Blantyre	Botha's Hill	DTTC-SU
Total Participants Enrolled ¹	142	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection ²	108	0	0	0	0
Progressed to Step 2	103/108 (95.4%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	3/108 (2.8%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	2/108 (1.9%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	1/108 (0.9%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	1/108 (0.9%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/108 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – May 12, 2018
Data through : May 12, 2018
Table 4 – Progression to Step 2 by Site

	Emavundleni	Gaborone	Isipingo	Kisumu	Lilongwe
Total Participants Enrolled ¹	0	12	0	0	0
Participants who have been enrolled for 6 weeks or received injection ²	0	7	0	0	0
Progressed to Step 2	0/0 (-%)	6/7 (85.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	0/0 (-%)	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	0/0 (-%)	1/7 (14.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	0/0 (-%)	1/7 (14.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	0/0 (-%)	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (-%)	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – May 12, 2018
Data through : May 12, 2018
Table 4 – Progression to Step 2 by Site

	MU-JHU	Parirenyatwa	Seke South	Soweto	Spilhaus
Total Participants Enrolled ¹	0	23	0	33	0
Participants who have been enrolled for 6 weeks or received injection ²	0	13	0	32	0
Progressed to Step 2	0/0 (–%)	12/13 (92.3%)	0/0 (–%)	31/32 (96.9%)	0/0 (–%)
Progression Status Pending	0/0 (–%)	1/13 (7.7%)	0/0 (–%)	0/32 (0.0%)	0/0 (–%)
Did Not Progress to Step 2	0/0 (–%)	0/13 (0.0%)	0/0 (–%)	1/32 (3.1%)	0/0 (–%)
Permanently discontinued from the study product	0/0 (–%)	0/13 (0.0%)	0/0 (–%)	0/32 (0.0%)	0/0 (–%)
Terminated from the study	0/0 (–%)	0/13 (0.0%)	0/0 (–%)	1/32 (3.1%)	0/0 (–%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (–%)	0/13 (0.0%)	0/0 (–%)	0/32 (0.0%)	0/0 (–%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for
Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – May 12, 2018
Data through : May 12, 2018
Table 4 – Progression to Step 2 by Site**

	St.Mary's Clinic	Swaziland	UVRI-IAVI	Verulam	Ward 21
Total Participants Enrolled ¹	26	0	0	0	32
Participants who have been enrolled for 6 weeks or received injection ²	13	0	0	0	28
Progressed to Step 2	13/13 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	27/28 (96.4%)
Progression Status Pending	0/13 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	1/28 (3.6%)
Did Not Progress to Step 2	0/13 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/28 (0.0%)
Permanently discontinued from the study product	0/13 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/28 (0.0%)
Terminated from the study	0/13 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/28 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/13 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/28 (0.0%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – May 12, 2018
Data through : May 12, 2018
Table 4 – Progression to Step 2 by Site

	Zengeza
Total Participants Enrolled ¹	16
Participants who have been enrolled for 6 weeks or received injection ²	15
Progressed to Step 2	14/15 (93.3%)
Progression Status Pending	1/15 (6.7%)
Did Not Progress to Step 2	0/15 (0.0%)
Permanently discontinued from the study product	0/15 (0.0%)
Terminated from the study	0/15 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/15 (0.0%)

¹ Inappropriately enrolled participants are excluded.

² Participants who did not progress to Step 2 due to HIV infection are not included.